Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Molecular Psychiatry

Volumn 9, Issue 7, 2004, Pages 705-710

  Hampel, H ^a   Teipel, S J ^a   Fuchsberger, T ^a   Andreasen, N ^b   Wiltfang, J ^c   Otto, M ^d   Shen, Y ^e   Dodel, R ^f   Du, Y ^g   Farlow, M ^g   Moller H J ^a   Blennow, K ^h   Buerger, K ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e SUN HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF BONN   (Germany)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease (AD); Beta amyloid; Biomarker; Cerebro spinal fluid (CSF); Conversion; Early diagnosis; Mild cognitive impairment (MCI); Prediction; Prognosis; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; NOOTROPIC AGENT; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 3142743789     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001473     Document Type: Article

References (34)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
2. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-118.
3. Galasko D, Clark C, Chang L, Miller B, Green RC, Rotter R et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997; 48: 632-635.
4. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996; 212: 209-211.
5. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-648.
6. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D et al. High cerebrospinal fluid tau and low amyloid-beta-42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-945.
7. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
8. Arai H, Nakagawa T, Kosaka Y, Higuchi M, Matsui T, Okamura N et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals. Alzheim Res 1997; 3: 211-213.
9. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B et al. Cerebrospinal fluid tau and A-beta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8.
10. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59: 1729-1734.
11. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-1781.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
13. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
14. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
15. Cox DR. Regression models and live-table. J R Statist Soc 1972; 34: 187-202.
16. Blennow K, Hampel H, Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613.
17. 1-42 proteins to phosphorylated tau protein. Brain Res Bull 2003; 61: 243-253.
18. 42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2002; 24: 87-97.
19. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52: 1555-1562.
20. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N et al. Cerebrospinal fluid amyloid beta(l-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001; 172: 433-436.
21. Jensen M, Basun H, Lannfeldt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 186: 189-191.
22. Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 1993; 41: 1029-1032.
23. Clarnette R, Almeida O, Forstl H, Paton A, Martins RN. Clinical characteristics of individuals with subjective memory loss in Western Australia: results from a cross-sectional survey. Int J Geriatr Psychiatry 2001; 16: 168-174.
24. Schofield PW, Marder K, Dooneief G, Jacobs DM, Sano M, Stern Y. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry 1997; 154: 609-615.
25. Jensen M, Schroeder J, Blomberg M, Engvall B, Pantel J, Ida N et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999; 45: 504-511.
26. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H et al. Longitudinal study of cerebrospinal fluid levels of tau, A-beta1-40, and A-beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44: 17-26.
27. Riemenschneider M, Schmolke M, Lautenschlager N, Guder WG, Vanderstichele H, Vanmechelen E et al. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000; 284: 85-88.
28. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y et al. Combination assay of CSF tau, A-beta1-40, A-beta1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998; 158: 134-140.
29. Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997; 148: 41-45.
30. Sjögren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanderstichele H et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neurol Transm 2000; 107: 563-579.
31. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59: 627-629.
32. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000; 166: 201-203.
33. Frank RA, Galasko D, Hampel H, Hardy J, De Leon M, Mehta PD et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003; 24: 521-536.
34. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease - a comparative CSF study. Arch Gen Psychiatry, (in press).